Privo Technologies, Inc. to Present Phase II Data for PRV111 in Head and Neck Squamous Cell Carcinoma at the Upcoming 2021 ASCO Annual Meeting

Privo Technologies, Inc. (“Privo”), a biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough on cancer, Easy on patients”, announced today a poster presentation on the safety and efficacy of PRV111 in patients with early-stage Head and Neck Squamous Cell Carcinoma (HNSCC). PRV111 is an anticancer topical patch that allows for locoregional treatment.

The poster presentation will be available at the 2021 ASCO Annual Meeting being held June 4-8, 2021.

Read more: https://www.prnewswire.com/news-releases/privo-technologies-inc-to-present-phase-ii-data-for-prv111-in-head-and-neck-squamous-cell-carcinoma-at-the-upcoming-2021-asco-annual-meeting-301305716.html